Lv52
830 积分 2026-06-07 加入
Adjuvant Durvalumab in Completely Resected Early-Stage Non–Small Cell Lung Cancer
2个月前
已完结
Where is the data? Delayed and chronic irAE surveillance and management after cessation of ICIs: expert insights from SITC on survivorship care and the need for long-term data
2个月前
已完结
Outcomes After Neoadjuvant Therapy With or Without Immunotherapy Followed By Pneumonectomy in Non-Small Cell Lung Cancer Patients
2个月前
已完结
Determinants of successful minimally invasive surgery (MIS) for resectable non-small cell lung cancer (NSCLC) after neoadjuvant therapy
2个月前
已完结
Outcomes After Neoadjuvant Therapy With or Without Immunotherapy Followed By Pneumonectomy in Non-Small Cell Lung Cancer Patients
2个月前
已完结
Impact of Neoadjuvant Therapy, Tumor Size, and Surgical Approach on Conversion to Open Thoracotomy During Lobectomy
2个月前
已完结
Minimally invasive resection of non–small cell lung cancer after chemoimmunotherapy: A multicenter study in academic hospitals
2个月前
已完结
Predicting therapeutic response to neoadjuvant immunotherapy based on an integration model in resectable stage IIIA (N2) non–small cell lung cancer
2个月前
已完结
SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non–Small-Cell Lung Cancer—A Multicenter Single-Arm Phase II Trial
4个月前
已完结
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer
4个月前
已完结
皖公网安备34019202002308
